Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 09 2020 - 8:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
November 2020 (No. 2)
Commission File Number
001-37846
CELLECT
BIOTECHNOLOGY LTD.
(Translation of registrant’s name
into English)
23 Hata’as Street
Kfar Saba, Israel 44425
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On November 8, 2020 Cellect Biotechnology
Ltd. (the “Company”) reconvened its annual general meeting of shareholders at which the Company’s ordinary shareholders
and ADS holders passed all agenda items as proposed, as described further in Exhibit 99.1 to the Company’s Form 6-K furnished
by the Company to the Securities and Exchange Commission on October 20, 2020.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Cellect Biotechnology Ltd.
|
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
|
Name: Eyal Leibovitz
|
Date: November 9, 2020
|
|
Title: Chief Financial Officer
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2023 to Sep 2024